Mycrodose Therapeutics

Mycrodose Therapeutics is a pharmaceutical company based in San Diego, California, founded in 2020.

The company specializes in developing Advanced Drug Delivery systems aimed at treating cancer-related conditions, mental health disorders, and cognitive degenerative diseases. Mycrodose is notable for its focus on psychedelic compounds and holds a Schedule I License from the U.S. Drug Enforcement Agency, allowing it to research substances like Psilocybin, LSD, MDMA, and DMT. The company’s proprietary IP-Protected Sustained Microdosing TechnologyTM enhances the delivery of pharmaceutical compounds. Mycrodose offers services in advanced drug delivery system development, psychedelic research, and clinical candidate identification. Its product pipeline includes a ketamine-based drug delivery device for oral mucositis, a transdermal psilocybin delivery system, and various formulations for mental health conditions. Mycrodose Therapeutics collaborates with academic institutions and healthcare organizations to advance its innovative drug solutions.